Literature DB >> 23202144

Disability caused by multiple sclerosis is associated with the number of extra cranial venous stenoses: possible improvement by venous angioplasty. Results of a prospective study.

M Denislic1, Z Milosevic, M Zorc, I Zuran D Ravnik, O Mendiz.   

Abstract

OBJECTIVE: Chronic cerebrospinal venous insufficiency (CCSVI) was recently described in patients with multiple sclerosis (MS). The hypothesis of the vascular aetiology provides a new approach in the investigation and treatment of MS.
METHODS: Our open-label study included 94 MS patients who fulfilled ultrasound sonographic criteria required for CCSVI. The internal jugular and/or azygous veins by a catheter venography were dilated.
RESULTS: In 34.8% of the patients unilateral, in 65.2% bilateral venous abnormalities and in 2.1% no luminal obstructions were demonstrated. The patient group with the higher disability score had a significantly higher number of venous lesions (P < 0.005). Significant improvement of clinical disability in relapsing-remitting patients was (P < 0.001) achieved. In our study no stents were used. Re-stenosis occurred in 21.7% of the patients.
CONCLUSION: The number of venous narrowings is higher in more disabled patients. A significant improvement in clinical disability in the relapsing-remitting group was observed.

Entities:  

Keywords:  angioplasty; interventional radiology; multiple sclerosis; venous pathology

Mesh:

Year:  2013        PMID: 23202144     DOI: 10.1258/phleb.2012.012065

Source DB:  PubMed          Journal:  Phlebology        ISSN: 0268-3555            Impact factor:   1.740


  7 in total

Review 1.  Chronic cerebrospinal venous insufficiency and multiple sclerosis: a comprehensive meta-analysis of case-control studies.

Authors:  Georgios Tsivgoulis; Theodoros N Sergentanis; Andrew Chan; Konstantinos Voumvourakis; Nikos Triantafyllou; Theodora Psaltopoulou; Ralf Gold; Christos Krogias
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

2.  Prospective randomized trial of venous angioplasty in MS (PREMiSe).

Authors:  Adnan H Siddiqui; Robert Zivadinov; Ralph H B Benedict; Yuval Karmon; Jihnhee Yu; Mary L Hartney; Karen L Marr; Vesela Valnarov; Cheryl L Kennedy; Murali Ramanathan; Deepa P Ramasamy; Kresimir Dolic; David W Hojnacki; Ellen Carl; Elad I Levy; L Nelson Hopkins; Bianca Weinstock-Guttman
Journal:  Neurology       Date:  2014-06-27       Impact factor: 9.910

Review 3.  The role of noninvasive and invasive diagnostic imaging techniques for detection of extra-cranial venous system anomalies and developmental variants.

Authors:  Kresimir Dolic; Adnan H Siddiqui; Yuval Karmon; Karen Marr; Robert Zivadinov
Journal:  BMC Med       Date:  2013-06-27       Impact factor: 8.775

4.  Internal jugular vein blood flow in multiple sclerosis patients and matched controls.

Authors:  Marcello Mancini; Roberta Lanzillo; Raffaele Liuzzi; Orlando Di Donato; Monica Ragucci; Serena Monti; Elena Salvatore; Vincenzo Brescia Morra; Marco Salvatore
Journal:  PLoS One       Date:  2014-03-27       Impact factor: 3.240

5.  Novel Compliant Scaffold with Specific Design for Venous System: Results of a Porcine Model Study.

Authors:  Pierfrancesco Veroux; Alessia Giaquinta; Carla Virgilio; Davide Danilo Zani; Giuliano Ravasio; Vincenzo Ardita; Paola Secchiero; Eugenio Scanziani; Paolo Zamboni; Massimiliano Veroux
Journal:  Biomed Res Int       Date:  2018-01-31       Impact factor: 3.411

6.  No association between variations in extracranial venous anatomy and clinical outcomes in multiple sclerosis patients over 5 years.

Authors:  Sirin Gandhi; Karen Marr; Marcello Mancini; Maria Grazia Caprio; Dejan Jakimovski; Avinash Chandra; Jesper Hagemeier; David Hojnacki; Channa Kolb; Bianca Weinstock-Guttman; Robert Zivadinov
Journal:  BMC Neurol       Date:  2019-06-11       Impact factor: 2.474

Review 7.  Potential involvement of the extracranial venous system in central nervous system disorders and aging.

Authors:  Robert Zivadinov; Chih-Ping Chung
Journal:  BMC Med       Date:  2013-12-17       Impact factor: 8.775

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.